Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
to formulate and lead a research programme that will deliver innovative, world-class science in molecular host-microbes interactions or a related field and good knowledge of JIC/NRP research fields, underpinning
-
Postdoctoral Fellow – Mitochondrial Microproteins & Therapeutic Innovation Lena Ho Lab | Duke-NUS Medical School, Singapore Cardiovascular & Metabolic Disorders Programme Advance scientific
-
Research Fellow (Fusion Shielding Materials) - School of Metallurgy and Materials - 105638 - Grade 7
requirements and use resources effectively Understanding of and ability to contribute to broader management/administration processes Contribute to the planning and organising of the research programme and/or
-
programme and/or specific research project Co-ordinate own work with others to avoid conflict or duplication of effort Knowledge of the protected characteristics of the Equality Act 2010, and how to actively
-
organising of the research programme and/or specific research project Co-ordinate own work with others to avoid conflict or duplication of effort Knowledge of the protected characteristics of the Equality Act
-
programme designated to attract and empower the world’s brightest early-career researchers. This fellowship supports outstanding scientists who harness Artificial Intelligence (AI) to accelerate breakthroughs
-
the project and the Programme team Contribute to writing bids for research funding Contribute to Departmental/School research-related activities and research-related administration Contribute to enterprise
-
NIH Cancer Postdoc Fellowships Available Train in the prestigious National Cancer Institute intramural program The Center for Cancer Research (CCR) in the National Cancer Institute has postdoctoral
-
learning and advanced statistical modeling * Proficient programming skills in Python and/or R, experience with machine learning and omics analysis libraries (e.g., scikit-learn, TensorFlow/PyTorch
-
oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor prognosis, and this clinic